Overview

This trial is active, not recruiting.

Condition multiple myeloma
Sponsor Celgene Corporation
Start date September 2009
End date December 2024
Trial size 3011 participants
Trial identifier NCT01081028, Connect ® MM

Summary

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016

Primary Outcomes

Measure
Identify and summarize patterns in therapeutic regimens
time frame: up to 8 years
Identify and summarize patterns in therapeutic regimens and patient outcomes
time frame: up to 8 years

Secondary Outcomes

Measure
Summarize Effectiveness of Treatment Regimens
time frame: up to 8 years
Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes
time frame: up to 8 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect®MM registry - Age ≥18 years - Willing and able to provide signed informed consent - Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel Exclusion Criteria: - None

Additional Information

Official title Connect® MM- The Multiple Myeloma Disease Registry
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Celgene Corporation.